Cost-effectiveness of tuberculosis screening and isoniazid treatment in the TB/HIV in Rio (THRio) Study

Int J Tuberc Lung Dis. 2014 Dec;18(12):1443-8. doi: 10.5588/ijtld.14.0108.

Abstract

Objective: To estimate the incremental cost-effectiveness of tuberculosis (TB) screening and isoniazid preventive therapy (IPT) among human immunodeficiency virus (HIV) infected adults in Rio de Janeiro, Brazil.

Design: We used decision analysis, populated by data from a cluster-randomized trial, to project the costs (in 2010 USD) and effectiveness (in disability-adjusted life years [DALYs] averted) of training health care workers to implement the tuberculin skin test (TST), followed by IPT for TST-positive patients with no evidence of active TB. This intervention was compared to a baseline of usual care. We used time horizons of 1 year for the intervention and 20 years for disease outcomes, with all future DALYs and medical costs discounted at 3% per year.

Results: Providing this intervention to 100 people would avert 1.14 discounted DALYs (1.57 undiscounted DALYs). The median estimated incremental cost-effectiveness ratio was $2273 (IQR $1779-$3135) per DALY averted, less than Brazil's 2010 per capita gross domestic product (GDP) of $11,700. Results were most sensitive to the cost of providing the training.

Conclusion: Training health care workers to screen HIV-infected adults with TST and provide IPT to those with latent tuberculous infection can be considered cost-effective relative to the Brazilian GDP per capita.

Publication types

  • Multicenter Study
  • Pragmatic Clinical Trial
  • Randomized Controlled Trial
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Allied Health Personnel / economics
  • Allied Health Personnel / education
  • Antitubercular Agents / economics*
  • Antitubercular Agents / therapeutic use*
  • Bacteriological Techniques / economics
  • Brazil / epidemiology
  • Coinfection*
  • Cost-Benefit Analysis
  • Decision Support Techniques
  • Disability Evaluation
  • Drug Costs*
  • HIV Infections / diagnosis
  • HIV Infections / economics*
  • HIV Infections / epidemiology
  • Humans
  • Inservice Training / economics
  • Isoniazid / economics*
  • Isoniazid / therapeutic use*
  • Latent Tuberculosis / diagnosis
  • Latent Tuberculosis / drug therapy*
  • Latent Tuberculosis / economics*
  • Latent Tuberculosis / epidemiology
  • Markov Chains
  • Mass Screening / economics*
  • Mass Screening / methods
  • Models, Economic
  • Predictive Value of Tests
  • Program Evaluation
  • Radiography, Thoracic / economics
  • Time Factors
  • Treatment Outcome
  • Tuberculin Test / economics

Substances

  • Antitubercular Agents
  • Isoniazid